Ikarian Capital »

Travere Therapeutics shares owned by Ikarian Capital

Quarter-by-quarter ownership of Travere Therapeutics (TVTX) shares owned by Ikarian Capital from 13F filings

Historical chart of Ikarian Capital investment in Travere Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Travere Therapeutics held by Ikarian Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Travere Therapeutics by Ikarian Capital

Quarter filed Position value Share count Share price at filing
2025-09-30 $9.7M 405k 23.90
2024-12-31 $394k 23k 17.42

More positions owned by Ikarian Capital

United Therapeutics Corporation Put Option (UTHR)
Spdr Series Trust S&p Biotech Put Option (XBI)
Genmab A/s Sponsored Ads (GMAB)
Bristol Myers Squibb Put Option (BMY)
Abivax Sa Sponsored Ads (ABVX)
Uniqure Nv Call Call Option
Insmed Com Par $.01 (INSM)
Ptc Therapeutics I (PTCT)
Ionis Pharmaceuticals (IONS)
Cidara Therapeutics Com New (CDTX)
Scholar Rock Hldg Corp Put Option (SRRK)
Rapt Therapeutics Com New (RAPT)
Maze Therapeatics (MAZE)
Soleno Therapeutics (SLNO)
Cytokinetics Com New (CYTK)

View all positions for Ikarian Capital

Top funds holding Travere Therapeutics

Henderson Group
BlackRock
Armistice Capital
Vanguard Group
Macquarie Group
Perceptive Advisors
Adage Capital Partners GP
State Street Corporation
FMR
Rock Springs Capital Management
Emerald Advisers
Geode Capital Management
Renaissance Technologies
Stephens Investment Management Group
Deutsche Bank Aktiengesellschaft

View all funds holding Travere Therapeutics